Mylan NV (MYL.OQ)
35.53USD
20 Jul 2018
$-0.11 (-0.31%)
$35.64
$35.61
$36.02
$35.40
1,426,581
1,407,421
$47.81
$29.44
About
Overall
| Beta: | 1.33 |
| Market Cap(Mil.): | $18,370.46 |
| Shares Outstanding(Mil.): | 515.45 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MYL.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 22.46 | 29.12 | 33.34 |
| EPS (TTM): | 1.58 | -- | -- |
| ROI: | 2.89 | 13.60 | 13.18 |
| ROE: | 6.81 | 15.30 | 15.09 |
U.S. court rejects Allergan bid to shield patents through tribe deal
A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.
UPDATE 2-U.S. court rejects Allergan bid to shield patents through tribe deal
July 20 A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.
Mylan signs U.S. license deal on Humira with AbbVie
AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.
Mylan signs U.S. license deal on Humira with AbbVie
July 17 AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.
Indivior warning on anti-opioid drug competition sends shares tumbling
British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.
BRIEF-Mylan Adds To Central Nervous System Portfolio With Launch Of Generic Exelon® Patch
* MYLAN ADDS TO CENTRAL NERVOUS SYSTEM PORTFOLIO WITH LAUNCH OF GENERIC EXELON® PATCH
FDA finds deficiencies in Mylan's generic Advair; shares fall
Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.
UPDATE 2-FDA finds deficiencies in Mylan's generic Advair; shares fall
* Shares fall 4.5 pct after market (Adds analyst comment; updates shares)
FDA finds deficiencies in Mylan's generic Advair
June 13 U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.
FDA approves Mylan drug as first biosimilar to Amgen's Neulasta
Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.
Estimates